Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis

Table 2 Association between csDMARDs and BMI with the presence of serum TNFi after 1 year of treatment

	OR	95% CI
Age	1.04	0.98–1.11
Male	0.59	0.17–2.14
Disease duration	0.93	0.88–0.99*
TNFi type (ref: infliximab)	0.46	0.15–1.39
csDMARD (ref: use of any csDMARD)	3.82	1.06–13.84*
BMI (ref: normal weight)	18.38	2.24–150.63*

The adjusted multivariable logistic regression analysis included 161 patients. Odds ratio (OR) and 95% confidence interval (CI) were calculated. *p value < 0.05 was considered statistically significant. TNFi tumour necrosis factor inhibitors, csDMARD conventional synthetic disease-modifying anti-rheumatic drug, BMI body mass index

ISSN: 1478-6362